Related Experiment Video
Updated: Jul 19, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates
Shannon L Meeks1, Cassandra D Josephson
1Aflac Cancer Center and Blood Disorders Service, Emory University/Children's Healthcare of Atlanta, USA. shannon.meeks@choa.org
Purpose Of Review:
To discuss the advantages and disadvantages of the albumin-free recombinant factor VIII concentrates in the treatment of hemophilia A.
Recent Findings:
The third-generation recombinant factor VIII product Advate has been found to be safe and effective in treating bleeding associated with hemophilia A.
Summary:
Multiple issues must be considered when selecting a factor VIII concentrate for patients with hemophilia A including efficacy, availability, risk of transmission of infectious agents, risk of inhibitor development and cost. Third-generation recombinant factor VIII concentrates have been shown to be safe and effective. A theoretical improvement in risk of infectious agent transmission has been achieved by production of the products without human or animal plasma proteins. Controversy exists, however, with regard to a higher risk of inhibitor development with recombinant products. The higher cost of Advate can also potentially play a role in product choice. Overall every patient and their family must be presented with the advantages and disadvantages of all factor VIII concentrates, and be allowed to make an informed decision about which product to use for treatment.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
09:35Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Distribution: Plasma Protein Binding
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.